NeuroMetrix (NURO) Reaches Diabetic Neuropathy Assessment Milestone with DPNCheck Device
Tweet Send to a Friend
NeuroMetrix (NASDAQ: NURO) reported that over 200,000 Medicare Advantage members have been assessed for diabetic neuropathy with the DPNCheck device.DPNCheck ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE